Altoida, Inc. is revolutionizing brain health through Precision Neurology, utilizing augmented reality and machine learning to pioneer digital #biomarkers of neurological disease. Founded in 2016 and headquartered in the United States, the company has garnered significant attention, securing a $14.00M Series A investment on 30 March 2022. This funding round was supported by a cohort of prominent investors, including Fyrfly Venture Partners, VI Partners, Alpana Ventures, Hikma Ventures, HonorHealth, MERL Ventures Fund, Whitecap Venture Partners, and b2venture.
Altoida's vision is underpinned by over 20 years of cutting-edge research in digital biomarkers, augmented reality, and artificial intelligence, propelling the company to create a new benchmark for measuring brain function and diagnosing neurological disease using just a smartphone or tablet. With its focus on AI, Digital Health, Health Care, Medical Devices, and VR/AR, Altoida's innovative approach holds substantial potential in transforming the landscape of neurological healthcare diagnostics.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Series A | $14.00M | 8 | 30 Mar 2022 | |
Funding Round | $498.34K | 1 | Alzheimer's Drug Discovery Foundation | 08 Sep 2021 |
Venture Round | Unknown | 1 | 06 Jul 2021 | |
Convertible Note | $2.00M | 1 | 28 Apr 2020 | |
Series A | $6.30M | 5 | 23 May 2019 |
No recent news or press coverage available for Altoida, Inc..